ABOUT THE PRODUCT:
Triple-dose serum to help improve volume loss, visibly reduce wrinkles & brighten dark spot appearance.
TEXTURE: A combination of three textures (gel, cream, & emulsion) that are blended in one triple-dose serum.
SKIN TYPE: Normal, Dry, Oily, Combination & Sensitive
SKIN CONCERN: Volume loss & plumping, fine lines, wrinkles, dark spots
FREE OFF: Sulfate-Free, Mineral Oil-Free
KEY INGREDIENTS & EFFECTS:
- Hyaluronic Acid:
Known for its ability to enhance moisture retention and hydration, which can help visibly plump and smooth skin appearance.
- C+Niacinamide:
A combination of Vitamin C and Niacinamide (Vitamin B3) helps target the appearance of dark spots, visibly brighten skin, and help smooth fine lines and wrinkles. - Ferulic Acid:
A powerful antioxidant helps to neutralize harmful free-radical damage and protect against oxidative stress that can accelerate skin aging.
WHAT IT DOES:
Discover the new era of Lancôme high-performance anti-aging inspired by regenerative skin sciences.
Patented innovation, Rénergie H.C.F. Triple Serum masterfully concentrates into one radically caring triple dose Hyaluronic Acid, C + Niacinamide and Ferulic Acid.
Each powerful alone, yet impossible to combine in one single formula, they now freshly fuse into a high performance anti-aging concentrate to restore skin layer by layer:
- LAYER 1: SKIN VOLUMETRY AND QUALITY RE-PLUMPED
- LAYER 2: PROGRESSIVE WRINKLE CORRECTION
- LAYER 3: DARK SPOTS TRIPLE CORRECTION
WHAT MAKES THE DIFFERENCE:
Tested for tolerance under dermatological control.
An highly effective, yet radically caring new kind of gesture. In a unparalleled study, 9 out of 10 women using luxury serums confirmed they would choose Rénergie H.C.F. Triple Serum over or additionally to their regular serum.
RESULTS:
Clinically Tested Results:
- Skin is more supple (+14.7%)*
- Skin is smoother (+30.1%)*
- Fine lines are reduced (-13.8%)*
- Wrinkles are reduced (-7.6%)*
- Dark spots are visibly smaller (-14.1%) and less intense (-15.0%)*
- Skin is firmer and less saggy (-12.0%)**
*Based on 8-week results in a clinical study of 45 women.